|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
4.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
61,438 |
159,721 |
184,721 |
409,721 |
Total Sell Value |
$4,291,798 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
Total People Sold |
3 |
3 |
3 |
3 |
Total Sell Transactions |
7 |
12 |
13 |
22 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kasinger James R. |
General Counsel and Secretary |
|
2022-12-05 |
4 |
D |
$52.26 |
$169,009 |
D/D |
(3,234) |
50,191 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-12-05 |
4 |
D |
$52.26 |
$1,013,896 |
D/D |
(19,401) |
310,878 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2022-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
53,425 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
330,279 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-11-28 |
4 |
AS |
$53.58 |
$1,350,827 |
D/D |
(25,000) |
290,279 |
|
-15% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-11-28 |
4 |
OE |
$19.12 |
$478,000 |
D/D |
25,000 |
315,279 |
|
- |
|
Smith Brendan |
Chief Financial Officer |
|
2022-10-17 |
4 |
D |
$55.76 |
$61,949 |
D/D |
(1,111) |
2,639 |
|
- |
|
Smith Brendan |
Chief Financial Officer |
|
2022-10-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-09-28 |
4 |
AS |
$64.58 |
$1,615,160 |
D/D |
(25,000) |
290,279 |
|
-24% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-09-28 |
4 |
OE |
$16.21 |
$405,250 |
D/D |
25,000 |
315,279 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-08-29 |
4 |
AS |
$66.14 |
$1,671,084 |
D/D |
(25,000) |
290,279 |
|
-27% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-08-29 |
4 |
OE |
$16.21 |
$405,250 |
D/D |
25,000 |
315,279 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-07-27 |
4 |
AS |
$75.64 |
$1,897,747 |
D/D |
(25,000) |
290,279 |
|
-36% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-07-27 |
4 |
OE |
$12.57 |
$374,918 |
D/D |
25,000 |
315,279 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-06-29 |
4 |
AS |
$61.42 |
$1,539,862 |
D/D |
(25,000) |
290,279 |
|
-19% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-06-29 |
4 |
OE |
$12.57 |
$314,250 |
D/D |
25,000 |
315,279 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2022-03-14 |
4 |
D |
$61.08 |
$75,067 |
D/D |
(1,229) |
26,797 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-03-14 |
4 |
D |
$61.08 |
$253,665 |
D/D |
(4,153) |
290,279 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2022-03-14 |
4 |
D |
$61.08 |
$63,462 |
D/D |
(1,039) |
46,429 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
28,026 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2022-03-11 |
4 |
D |
$62.56 |
$117,800 |
D/D |
(1,883) |
25,026 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
294,432 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-03-11 |
4 |
D |
$62.56 |
$343,267 |
D/D |
(5,487) |
285,432 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
47,468 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2022-03-11 |
4 |
D |
$62.56 |
$82,642 |
D/D |
(1,321) |
45,218 |
|
- |
|
483 Records found
|
|
Page 3 of 20 |
|
|